Aligos Therapeutics, Inc. (30)

Browse by Contract Category

Contracts

Consulting agreement by and between Aligos Therapeutics, Inc. and Kathleen Glaub, dated June 17, 2021 (Filed With SEC on August 5, 2021)
Form of Underwriting Agreement (Filed With SEC on June 28, 2021)
Description of Securities (Filed With SEC on March 23, 2021)
Form of Indemnification Agreement for directors and officers (Filed With SEC on October 9, 2020)
First Amendment to License Agreement by and between Aligos Therapeutics, Inc. and Emory University, dated June 18, 2020 (Filed With SEC on September 25, 2020)
Lease between Aligos Therapeutics, Inc. and Britannia Biotech Gateway Limited Partnership, dated June 21, 2018 (Filed With SEC on September 25, 2020)
Consulting Agreement by and between Aligos Therapeutics, Inc. and Kathy Glaub, dated June 17, 2021 (Filed With SEC on June 28, 2021)
Form of Change in Control and Severance Agreement (Filed With SEC on May 10, 2021)
Employment Agreement by and between Aligos Therapeutics, Inc. and Julian Symons, D.Phil., effective as of May 14, 2019 (Filed With SEC on May 10, 2021)
Amended and Restated Employment Agreement, effective as of February 10, 2021, by and between the Company and Lawrence M. Blatt (Filed With SEC on May 10, 2021)
Amended and Restated Employment Agreement, effective as of February 10, 2021, by and between the Company and Leonid Beigelman (Filed With SEC on May 10, 2021)
2020 Employee Stock Purchase Plan (Filed With SEC on October 9, 2020)
Non-Employee Director Compensation Program (Filed With SEC on October 9, 2020)
Confirmatory Employment Letter by and between Aligos Therapeutics, Inc. and Lucinda Quan, J.D., dated May 14, 2019 (Filed With SEC on October 9, 2020)
Employment Agreement by and between Aligos Therapeutics, Inc. and Leonid Beigelman, Ph.D., dated August 16, 2018 (Filed With SEC on October 9, 2020)
Employment Agreement by and between Aligos Therapeutics, Inc. and Lawrence M. Blatt, Ph.D., dated August 16, 2018 (Filed With SEC on October 9, 2020)
Form of Restricted Stock Unit Award Grant Notice under the 2020 Incentive Award Plan (Filed With SEC on October 9, 2020)
Form of Restricted Stock Award Agreement under the 2020 Incentive Award Plan (Filed With SEC on October 9, 2020)
Form of Stock Option Grant Notice and Stock Option Agreement under the 2020 Incentive Award Plan (Filed With SEC on October 9, 2020)
2020 Incentive Award Plan (Filed With SEC on October 9, 2020)
Amended and Restated Investors Rights Agreement dated October 9, 2020 (Filed With SEC on October 9, 2020)
Form of Common Stock Certificate (Filed With SEC on October 9, 2020)
Form of Underwriting Agreement (Filed With SEC on October 9, 2020)
Form of International Stock Option Grant Notice and Stock Option Agreement under 2018 Equity Incentive Plan, as amended (Filed With SEC on September 25, 2020)
Form of Early Exercise Stock Option Grant Notice and Stock Option Agreement under 2018 Equity Incentive Plan, as amended (Filed With SEC on September 25, 2020)
Form of Stock Option Grant Notice and Stock Option Agreement under 2018 Equity Incentive Plan, as amended (Filed With SEC on September 25, 2020)
2018 Equity Incentive Plan, as amended (Filed With SEC on September 25, 2020)
Amendment to License Agreement by and between Aligos Therapeutics, Inc. and Luxna Biotech Co., Ltd., dated April 8, 2020 (Filed With SEC on September 25, 2020)
License Agreement by and between Aligos Therapeutics, Inc. and Luxna Biotech Co., Ltd., dated December 19, 2018 (Filed With SEC on September 25, 2020)
Aligos Therapeutics/Emory University License Agreement by and between Aligos Therapeutics, Inc. and Emory University, dated June 26, 2018 (Filed With SEC on September 25, 2020)